By Matt Grossman

Abiomed Inc. has received the U.S. Food and Drug Administration's breakthrough-device designation for its Impella ECP heart pump, the company said Wednesday. The designation grants the device priority review.

The pump--which Abiomed says is the world's smallest--is meant to support heart function in people with heart disease. The small size would allow the device to be used in more procedures, Abiomed said.

The FDA's designation follows positive clinical data from the first 21 patients to be treated with the device, which is inserted into a patient's heart.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

08-18-21 0826ET